News

Business
Events
R&D Updates

March 25, 2021

2 min read

Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital

Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely

‹ Newer Posts

OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS

Contact

info@leydenlabs.com

Media inquiries

media@leydenlabs.com

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands

Leyden Labs Asia Pte. Ltd.

79 Science Park Drive
#04-05, Cintech IV
Singapore 118264